---
search:
  boost: 2 
---

# Electrolyte Depleter Agents

This is a subcategory of Genitourinary Agents.

## Decision Tree

- [Electrolyte Depleter Agents - Auryxia, Lanthanum Carbonate, Velphoro](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQkgxSklIRlVWSzdFNjQwVzY5VVVHQ1lKSSQlQCN0PWcu&topview=Preview)

## Formulary

### Preferred

| Preferred         | Generic Name | Quantity | Time (Days) |
| :---------------- | :----------- | :------: | :---------: |
| Calcium Acetate   |              |          |             |
| Calcium Carbonate |              |          |             |
| Phoslyra          |              |          |             |
| Sevelamer         |              |          |             |

### Non-Preferred

| Non-Preferred       | Generic Name | Quantity | Time (Days) |
| :------------------ | :----------- | :------: | :---------: |
| Auryxia             |              |          |             |
| Lanthanum Carbonate |              |          |             |
| Velphoro            |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **7 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=71)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=25)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
